Drug Trial Radar · NCT01638910
Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects
Last checked: Nov 20, 2026Latest source record: Dec 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
955
Actual
Start
Jun 2012
Primary completion
Nov 2014
Study completion Nov 2014
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jul 12, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of a combined oral contraceptive of estradiol valerate and dienogest in healthy female subjects.
Conditions
- Contraception
Interventions
EV/DNG (Qlaira, BAY86-5027)Drug
Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of unintended pregnanciesTime frame: Up to Cycle 13 (1 Cycle = 28 days)
Locations
39 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Chongqing, China
Site not named
Chongqing, China
Site not named
Chongqing, China
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Tianjin, China
Site not named
Guangzhou, Guangdong, China
Site not named
Guangzhou, Guangdong, China
Site not named
Shijiazhuang, Hebei, China
Site not named
Wuhan, Hubei, China
Site not named
Wuhan, Hubei, China
Site not named
Changsha, Hunan, China
Site not named
Hengyang, Hunan, China
Site not named
Nanjing, Jiangsu, China
Site not named
Dalian, Liaoning, China
Site not named
Shenyang, Liaoning, China
Site not named
Jinan, Shandong, China
Site not named
Chengdu, Sichuan, China
Site not named
Wenzhou, Zhejiang, China
Site not named
Hong Kong, Hong Kong
Site not named
Chandigarh, India
Site not named
Karnāl, India
Site not named
New Delhi, India
Site not named
Pune, India
Site not named
Secunderabad, India
Site not named
Pune, Maharashtra, India
Site not named
Kaohsiung City, Taiwan
Site not named
Taichung, Taiwan
Site not named
Taipei, Taiwan
Site not named
Taipei, Taiwan
Site not named
Taoyuan, Taiwan
Site not named
Taipei, Taipei, Taiwan
Site not named
Bangkok, Thailand
Site not named
Chiang Mai, Thailand
Site not named
Bangkok, Thailand, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.